Cancer

March 17, 2018

Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 17/March/2018, 7.23 am

Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 17/March/2018, 7.23 am https://genomediscovery.org/wp-content/uploads/2018/03/Xylobiose-functions-as-an-antimetastatic-agent.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/03/Xylobiose-functions-as-an-antimetastatic-agent.jpg March 17, 2018 March 17, 2018

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

March 15, 2018

Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors TIMP3 and CCM3/KRIT1 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 15/March/2017, 11,23 pm

Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors TIMP3 and CCM3/KRIT1 , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 15/March/2017, 11,23 pm https://genomediscovery.org/wp-content/uploads/2018/03/Xylobiose-functions-as-an-antimetastatic-agent-through-induction-of-TIMP3-and-CCM3jpg.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/03/Xylobiose-functions-as-an-antimetastatic-agent-through-induction-of-TIMP3-and-CCM3jpg.jpg March 15, 2018 March 15, 2018

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

February 23, 2018

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 23/February/2018, 6.07 am

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 23/February/2018, 6.07 am https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-BigH3-and-TIPE2-and-promote-metastatic-suppression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-BigH3-and-TIPE2-and-promote-metastatic-suppression.jpg February 23, 2018 February 23, 2018

From significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

February 21, 2018

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 22/February/2018, 12.06 am

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 22/February/2018, 12.06 am https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-BTG2-and-INK4a-and-promote-metastatic-suppression.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/DHA-and-Asp-induce-the-exp-of-metastassis-suppressors-BTG2-and-INK4a-and-promote-metastatic-suppression.jpg February 21, 2018 February 21, 2018

From significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

February 21, 2018

Combinatorial therapy for Cancer: A therapeutic mix encompassing Gedunin, Atorvastatin, Desipramine, Sulfasalazine (SSZ), SAHA(suberanilohydroxamic acid)/Vorinostat (GADSS) increases the expression of REV-ERBa, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 21/February/2018, 6.55 am

Combinatorial therapy for Cancer: A therapeutic mix encompassing Gedunin, Atorvastatin, Desipramine, Sulfasalazine (SSZ), SAHA(suberanilohydroxamic acid)/Vorinostat (GADSS) increases the expression of REV-ERBa, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 21/February/2018, 6.55 am https://genomediscovery.org/wp-content/uploads/2018/02/GADSS-inhibits-cancer-progression-through-induction-of-REVERB-α.β-and-a-number-of-other-tumor-suppressor-genes.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/GADSS-inhibits-cancer-progression-through-induction-of-REVERB-α.β-and-a-number-of-other-tumor-suppressor-genes.jpg February 21, 2018 February 21, 2018

Introduction:What they say: A recent study from Regulatory Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037, USA and Laboratory of Genetics, Salk Institute for Biological Studies, La…

February 21, 2018

Natural product-based combinatorial therapy for PTEN-deficient cancer: A therapeutic mix encompassing macbecin, temozolomide, EGCG, salinomycin, fluvastatin and chloroquine (MTESFC) decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancers, 21/February/2018, 6.29 am

Natural product-based combinatorial therapy for PTEN-deficient cancer: A therapeutic mix encompassing macbecin, temozolomide, EGCG, salinomycin, fluvastatin and chloroquine (MTESFC) decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancers, 21/February/2018, 6.29 am https://genomediscovery.org/wp-content/uploads/2018/02/Macbecin-Temozolomide-EGCG-Salinomycin-Fluvastatin-and-Chloroquine-MTESFC-inhibits-the-progressino-of-PTEN-deficient-human-cancers.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/Macbecin-Temozolomide-EGCG-Salinomycin-Fluvastatin-and-Chloroquine-MTESFC-inhibits-the-progressino-of-PTEN-deficient-human-cancers.jpg February 21, 2018 February 21, 2018

Introduction: What they say: A study from the Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA shows that “Synthetic essentiality of chromatin remodelling…

Popular Post